{"schema_version":"1","generated_at":"2026-10-29T06:30:39.480Z","data_as_of":null,"url":"https://www.findmykol.com/kol/james-mccloskey-nj","json_url":"https://www.findmykol.com/kol/james-mccloskey-nj/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"james-mccloskey-nj","name":"James McCloskey","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Hackensack University Medical Center","institution_url":"https://www.findmykol.com/institution/hackensack-university-medical-center","city":"Hackensack","state":"NJ","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1992951149","openalex":"A5006561610"},"summary":"James McCloskey is an Oncology physician affiliated with Hackensack University Medical Center. OpenAlex indexes 160 publications with 2,271 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":160,"cited_by_count":2271,"h_index":21,"latest_activity_year":2025,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT02846376","title":"Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant","phase":"PHASE1","status":"TERMINATED","role":"Overall official","sponsor":"Hackensack Meridian Health","source_url":"https://clinicaltrials.gov/study/NCT02846376","trial_url":"https://www.findmykol.com/trial/NCT02846376"}],"source":"trials"},"payments":{"company_count":43,"program_years":{"first":2021,"last":null},"rows_total":103,"shown":3,"withheld":100,"rows":[{"payer":"GlaxoSmithKline, LLC.","program_year":2025,"amount_usd":108112.47,"payment_count":66,"source_url":"https://openpaymentsdata.cms.gov/search?query=1992951149"},{"payer":"Syndax Pharmaceuticals, Inc.","program_year":2025,"amount_usd":100148.56,"payment_count":47,"source_url":"https://openpaymentsdata.cms.gov/search?query=1992951149"},{"payer":"SOBI, INC","program_year":2025,"amount_usd":68815.27,"payment_count":36,"source_url":"https://openpaymentsdata.cms.gov/search?query=1992951149"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1992951149","source":"payments"},"prescribing":{"data_year":2024,"areas_total":6,"areas_shown":3,"areas":[{"area":"Blood & clotting","share_pct":89.8,"classes_total":2,"classes":[{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":89.5,"drugs":[{"name":"Epoetin alfa","share_pct":100}],"max_beneficiaries":25},{"class":"Thrombopoietin Receptor Agonist","setting":"prescribed","share_pct":0.3,"drugs":[{"name":"Promacta","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":8.2,"classes_total":6,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":5.5,"drugs":[{"name":"Jakafi","share_pct":39.7},{"name":"Sprycel","share_pct":14.5},{"name":"Imatinib Mesylate","share_pct":13.4},{"name":"Ayvakit","share_pct":8.8},{"name":"Bosulif","share_pct":8.8},{"name":"Tasigna","share_pct":8},{"name":"Iclusig","share_pct":3.5},{"name":"Dasatinib","share_pct":3.2}],"max_beneficiaries":null},{"class":"Nucleoside Metabolic Inhibitor","setting":"prescribed","share_pct":1.2,"drugs":[{"name":"Inqovi","share_pct":80},{"name":"Onureg","share_pct":20}],"max_beneficiaries":null}]},{"area":"Anti-infectives","share_pct":0.8,"classes_total":2,"classes":[{"class":"Azole Antifungal","setting":"prescribed","share_pct":0.6,"drugs":[{"name":"Posaconazole","share_pct":100}],"max_beneficiaries":23},{"class":"Short-acting sulfonamides","setting":"prescribed","share_pct":0.2,"drugs":[{"name":"Sulfamethoxazole-Trimethoprim","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":94.4,"facility_pct":5.6},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AML","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-25-01694","status":"verified"},{"title":"Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study","year":2025,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-025-01245-5","status":"verified"},{"title":"Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-764","status":"verified"},{"title":"Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia","year":2024,"journal":"JAMA","source_url":"https://doi.org/10.1001/jama.2024.4783","status":"verified"},{"title":"First‐in‐human study of <scp>JNJ</scp>‐67571244, a <scp>CD33</scp> × <scp>CD3</scp> bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome","year":2024,"journal":"Clinical and Translational Science","source_url":"https://doi.org/10.1111/cts.13742","status":"verified"}],"source":"works"},"contact":{"address_1":"92 2ND ST","city":"Hackensack","state":"NJ","zip":"076012191","phone":"551-996-3925","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1992951149","source":"identity"},"similar":[{"name":"Steven Ghanny","slug":"steven-ghanny","institution":"Hackensack University Medical Center","specialty":"Pediatric Endocrinology","url":"https://www.findmykol.com/kol/steven-ghanny","json_url":"https://www.findmykol.com/kol/steven-ghanny/profile.json"},{"name":"Andre Goy","slug":"andre-goy","institution":"Hackensack University Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/andre-goy","json_url":"https://www.findmykol.com/kol/andre-goy/profile.json"},{"name":"David Vesole","slug":"david-vesole","institution":"Hackensack University Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/david-vesole","json_url":"https://www.findmykol.com/kol/david-vesole/profile.json"},{"name":"Martin Gutierrez","slug":"martin-gutierrez","institution":"Hackensack University Medical Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/martin-gutierrez","json_url":"https://www.findmykol.com/kol/martin-gutierrez/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":100,"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-01-26","provider_certified":"2022-01-26","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}